FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2741738679> ?p ?o ?g. }

• W2741738679 endingPage "68598" @default.
• W2741738679 startingPage "68591" @default.
• W2741738679 abstract "// Aixia Sui 1, 2 , Yongbing Xu 2 , Yitong Li 2 , Qilu Hu 2 , Zeyang Wang 2 , Hongtao Zhang 2 , Junjie Yang 2 , Xiaoqiang Guo 4, 5 and Wenqing Zhao 1, 3 1 Faculty of Graduate Studies, Hebei Medical University, Shijiazhuang 050081, Hebei, China 2 Department of Oncology, Hebei General Hospital, Shijiazhuang 050051, Hebei, China 3 Department of Neurosurgery, Hebei General Hospital, Shijiazhuang 050051, Hebei, China 4 State Engineering Laboratory of Medical Key Technologies Application of Synthetic Biology, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, The First Affliated Hospital of Shenzhen University, Shenzhen 518035, Guangdong, China 5 Department of Urology, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU-HKUST Medical Center, Shenzhen 518036, Guangdong, China Correspondence to: Wenqing Zhao, email: hbghwenqingzhao@126.com Xiaoqiang Guo, email: xiaoqiangguo123@163.com Keywords: glioma, histone demethylase, JMJD3, inhibitor, GSK-J4 Abbreviations: JMJD3: jumonji domain-containing protein 3; KDM6B: lysine-specific demethylase 6B; CCK-8: Cell Counting Kit-8; K27M: lysine (K) 27 to methionine (M) mutation Received: March 31, 2017      Accepted: June 28, 2017      Published: August 02, 2017 ABSTRACT Glioma is regarded as the most prevalent malignant carcinoma of the central nervous system, and lack of effective treatment. Thus, the development of new therapeutic strategies targeting glioma is of significant clinical importance. In the present study, histone H3K27 demethylase jumonji domain-containing protein 3 (JMJD3) was investigated as target for glioma treatment. The mRNA of JMJD3 was overexpressed in glioblastoma tissues compared to normal brain tissues ( P <0.05). The content of JMJD3 was also higher in glioma cells than in human brain microvascular endothelial cell (hCMEC), and the corresponding level of H3K27me3 was decreased ( P <0.05). The treatment with JMJD3 specific inhibitor GSK-J4 can increase the content of H3K27me3 in glioma cells, which means the activity of JMJD3 was inhibited. GSK-J4 can inhibit glioma cell proliferation in a concentration dependent and time-dependent manner ( P <0.05). GSK-J4 also induced glioma cell apoptosis and inhibited cell migration ( P <0.05). But there was no obvious effect of GSK-J4 on hCMEC cells. All together, these data suggest that GSK-J4 has important potential in the gliomas treatment." @default.
• W2741738679 created "2017-08-08" @default.
• W2741738679 creator A5007004838 @default.
• W2741738679 creator A5008397179 @default.
• W2741738679 creator A5011036962 @default.
• W2741738679 creator A5023546935 @default.
• W2741738679 creator A5034514825 @default.
• W2741738679 creator A5050530612 @default.
• W2741738679 creator A5051624923 @default.
• W2741738679 creator A5059845740 @default.
• W2741738679 creator A5073305279 @default.
• W2741738679 date "2017-08-02" @default.
• W2741738679 modified "2023-10-14" @default.
• W2741738679 title "The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cells" @default.
• W2741738679 cites W1971180847 @default.
• W2741738679 cites W1989297227 @default.
• W2741738679 cites W1991572801 @default.
• W2741738679 cites W2008721015 @default.
• W2741738679 cites W2011965633 @default.
• W2741738679 cites W2015735594 @default.
• W2741738679 cites W2022930470 @default.
• W2741738679 cites W2026848327 @default.
• W2741738679 cites W2036044314 @default.
• W2741738679 cites W2044197183 @default.
• W2741738679 cites W2051921450 @default.
• W2741738679 cites W2061973650 @default.
• W2741738679 cites W2062927905 @default.
• W2741738679 cites W2098052125 @default.
• W2741738679 cites W2101775250 @default.
• W2741738679 cites W2134925003 @default.
• W2741738679 cites W2149176006 @default.
• W2741738679 cites W2157495337 @default.
• W2741738679 cites W2158233796 @default.
• W2741738679 cites W2185909429 @default.
• W2741738679 cites W2288988715 @default.
• W2741738679 cites W2290765198 @default.
• W2741738679 cites W2294672181 @default.
• W2741738679 cites W2320579304 @default.
• W2741738679 cites W2346893706 @default.
• W2741738679 cites W2479296771 @default.
• W2741738679 cites W2508408314 @default.
• W2741738679 cites W2531255230 @default.
• W2741738679 cites W2543213157 @default.
• W2741738679 cites W2593125811 @default.
• W2741738679 cites W2417490340 @default.
• W2741738679 doi "https://doi.org/10.18632/oncotarget.19793" @default.
• W2741738679 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5620280" @default.
• W2741738679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28978140" @default.
• W2741738679 hasPublicationYear "2017" @default.
• W2741738679 type Work @default.
• W2741738679 sameAs 2741738679 @default.
• W2741738679 citedByCount "40" @default.
• W2741738679 countsByYear W27417386792018 @default.
• W2741738679 countsByYear W27417386792019 @default.
• W2741738679 countsByYear W27417386792020 @default.
• W2741738679 countsByYear W27417386792021 @default.
• W2741738679 countsByYear W27417386792022 @default.
• W2741738679 countsByYear W27417386792023 @default.
• W2741738679 crossrefType "journal-article" @default.
• W2741738679 hasAuthorship W2741738679A5007004838 @default.
• W2741738679 hasAuthorship W2741738679A5008397179 @default.
• W2741738679 hasAuthorship W2741738679A5011036962 @default.
• W2741738679 hasAuthorship W2741738679A5023546935 @default.
• W2741738679 hasAuthorship W2741738679A5034514825 @default.
• W2741738679 hasAuthorship W2741738679A5050530612 @default.
• W2741738679 hasAuthorship W2741738679A5051624923 @default.
• W2741738679 hasAuthorship W2741738679A5059845740 @default.
• W2741738679 hasAuthorship W2741738679A5073305279 @default.
• W2741738679 hasBestOaLocation W27417386791 @default.
• W2741738679 hasConcept C104317684 @default.
• W2741738679 hasConcept C126322002 @default.
• W2741738679 hasConcept C143998085 @default.
• W2741738679 hasConcept C2778227246 @default.
• W2741738679 hasConcept C2781364455 @default.
• W2741738679 hasConcept C502942594 @default.
• W2741738679 hasConcept C54355233 @default.
• W2741738679 hasConcept C64927066 @default.
• W2741738679 hasConcept C71924100 @default.
• W2741738679 hasConcept C86803240 @default.
• W2741738679 hasConceptScore W2741738679C104317684 @default.
• W2741738679 hasConceptScore W2741738679C126322002 @default.
• W2741738679 hasConceptScore W2741738679C143998085 @default.
• W2741738679 hasConceptScore W2741738679C2778227246 @default.
• W2741738679 hasConceptScore W2741738679C2781364455 @default.
• W2741738679 hasConceptScore W2741738679C502942594 @default.
• W2741738679 hasConceptScore W2741738679C54355233 @default.
• W2741738679 hasConceptScore W2741738679C64927066 @default.
• W2741738679 hasConceptScore W2741738679C71924100 @default.
• W2741738679 hasConceptScore W2741738679C86803240 @default.
• W2741738679 hasIssue "40" @default.
• W2741738679 hasLocation W27417386791 @default.
• W2741738679 hasLocation W27417386792 @default.
• W2741738679 hasLocation W27417386793 @default.
• W2741738679 hasLocation W27417386794 @default.
• W2741738679 hasOpenAccess W2741738679 @default.
• W2741738679 hasPrimaryLocation W27417386791 @default.
• W2741738679 hasRelatedWork W1973718276 @default.
• W2741738679 hasRelatedWork W2030397414 @default.

• next